

**OVATION SCIENCE INC.**

Condensed Consolidated Interim Financial Statements

For the Three and Nine Months Ended September 30, 2019

*Expressed in Canadian dollars*

*(Unaudited)*

## **NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

The accompanying unaudited condensed consolidated interim financial statements for Ovation Science Inc. (the "Company") have been prepared by management in accordance with International Financing Reporting Standards ("IFRS"). These condensed consolidated interim financial statements, which are the responsibility of management, are unaudited and have not been reviewed by the Company's auditors. The Company's Audit Committee and Board of Directors have reviewed and approved these condensed consolidated interim financial statements. In accordance with the disclosure requirements of National Instrument 51-102 released by the Canadian Securities Administrators, the Company's independent auditors have not performed a review of these condensed consolidated interim financial statements.

**OVATION SCIENCE INC.**

Condensed Consolidated Interim Statement of Financial Position  
(Expressed in Canadian dollars)

	Note	As at September 30, 2019 (Unaudited)	As at December 31, 2018
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents		\$ 1,190,230	\$ 468,969
Short-term investments		-	1,503,025
Trade and other receivables	3	61,341	52,196
Prepaid expenses		40,776	25,528
Inventory	4	96,639	68,750
		1,388,986	2,118,468
License	5	606,812	606,812
Property, plant and equipment		98,963	-
<b>Total assets</b>		<b>\$ 2,094,761</b>	<b>\$ 2,725,280</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>			
<b>Current liabilities</b>			
Accounts payable and other liabilities	6	\$ 98,679	\$ 197,226
Convertible notes	7	286,278	279,730
Derivative liability	7	11,621	58,845
<b>Total liabilities</b>		<b>396,578</b>	<b>535,841</b>
<b>Shareholders' equity</b>			
Share capital	8	1,940,692	1,900,518
Reserves	9	860,804	858,866
Deficit		(1,103,313)	(569,945)
		1,698,183	2,189,439
<b>Total liabilities and shareholders' equity</b>		<b>\$ 2,094,761</b>	<b>\$ 2,725,280</b>

Nature of business and going concern (Note 1)

Subsequent events (Note 12)

**These condensed consolidated interim financial statements were approved by the Board of Directors on November 28, 2019:**

"Logan Anderson"

Director

"Terry Howlett"

Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

**OVATION SCIENCE INC.**

## Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

(Expressed in Canadian dollars)

(Unaudited)

	Note	Three months ended September 30,		Nine months ended September 30,	
		2019	2018	2019	2018
<b>Revenue</b>					
Polymer sales	\$	-	28,924	\$ 20,668	46,903
Royalty fees		78,908	-	173,107	-
		78,908	28,924	193,775	46,903
<b>Cost of sales</b>	4	4,935	8,518	16,689	20,030
<b>Gross margin</b>		73,973	20,406	177,086	26,873
<b>Operating expenses</b>					
Management and director fees	10	91,569	49,500	262,858	148,500
Advertising and promotion		16,768	-	123,150	-
Office and general		67,291	11,187	142,008	35,253
Professional fees		40,987	24,605	94,064	76,689
Product development		21,690	4,726	64,851	26,478
Share-based payments	9	-	-	14,432	12,980
Investor relations		31,449	-	31,449	-
Bad debt		8,751	-	8,751	-
		278,505	90,018	741,563	299,900
<b>Loss from operations</b>		(204,532)	(69,612)	(564,477)	(273,027)
<b>Other income (expenses)</b>					
Interest expense		(5,780)	(9,523)	(22,739)	(9,523)
Accretion expense	7	(2,090)	(873)	(6,548)	(17,974)
Interest income		2,650	-	20,638	-
Change in fair value of derivative liability	7	72,304	-	47,224	-
Foreign exchange loss		(3,713)	(66)	(7,466)	(2,168)
<b>Loss and comprehensive loss</b>	\$	(141,161)	(80,074)	\$ (533,368)	(302,692)
<b>Loss per share – basic and diluted</b>	\$	(0.01)	(0.01)	\$ (0.02)	(0.02)
<b>Basic and diluted weighted average number of common shares outstanding</b>		23,248,050	15,103,121	23,193,485	15,103,121

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

**OVATION SCIENCE INC.**

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity

(Expressed in Canadian dollars)

(Unaudited)

	Share capital		Reserves	Deficit	Total shareholders' equity
	Number	Amount			
<b>Balance at December 31, 2017</b>	15,103,121	\$ 626,952	-	(61,541)	565,411
Equity portion of convertible note	-	-	3,245	-	3,245
Share-based payments	-	-	12,980	-	12,980
Loss for the period	-	-	-	(302,692)	(302,692)
<b>Balance at September 30, 2018</b>	15,103,121	\$ 626,952	\$ 16,225	\$ (364,233)	\$ 278,944
<b>Balance at December 31, 2018</b>	23,153,121	\$ 1,900,518	\$ 858,866	\$ (569,945)	\$ 2,189,439
Options exercised	60,000	26,660	(8,660)	-	18,000
Warrants exercised	21,510	13,514	(3,834)	-	9,680
Share-based payments	-	-	14,432	-	14,432
Loss for the period	-	-	-	(533,368)	(533,368)
<b>Balance at September 30, 2019</b>	23,234,631	\$ 1,940,692	\$ 860,804	\$ (1,103,313)	\$ 1,698,183

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

**OVATION SCIENCE INC.**

## Condensed Consolidated Interim Statements of Cash Flows

(Expressed in Canadian dollars)

(Unaudited)

	<b>Nine months ended September 30, 2019</b>	<b>Nine months ended September 30, 2018</b>
<b>OPERATING ACTIVITIES</b>		
Loss for the period	\$ (533,368)	\$ (302,692)
Adjustments for non-cash items:		
Accretion expense	6,548	-
Interest expense	22,739	-
Share-based payments	14,432	12,980
Change in fair value of derivative liability	(47,224)	-
Unrealized foreign exchange loss	7,466	3,326
Amortization on discount of debt	-	17,974
Changes in working capital items:		
Trade and other receivables	(6,120)	(9,339)
Inventory	(71,111)	(4,340)
Prepaid expense	27,974	(9,375)
Accounts payable and other liabilities	(128,792)	106,540
<b>Cash flows used in operating activities</b>	<b>(707,456)</b>	<b>(184,925)</b>
<b>INVESTING ACTIVITIES</b>		
Property, plant and equipment	(98,963)	-
Short-term investment	1,500,000	-
<b>Cash flows provided by investing activities</b>	<b>1,401,037</b>	<b>-</b>
<b>FINANCING ACTIVITIES</b>		
Repayment of promissory notes	-	(325,413)
Proceeds from issuance of shares	27,680	-
Proceeds from convertible notes	-	130,731
Proceeds from related party notes	-	105,124
Proceeds from promissory notes	-	150,000
<b>Cash flows (used) provided by financing activities</b>	<b>27,680</b>	<b>60,442</b>
Change in cash and cash equivalents	721,261	(124,483)
Cash and cash equivalents, beginning	468,969	277,956
<b>Cash and cash equivalents, ending</b>	<b>\$ 1,190,230</b>	<b>\$ 153,473</b>

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

## **OVATION SCIENCE INC.**

Notes to the Condensed Consolidated Interim Financial Statements  
For the three and nine months ended September 30, 2019 and 2018  
(Expressed in Canadian dollars)  
(Unaudited)

---

---

### **1. NATURE OF BUSINESS AND GOING CONCERN**

Ovation Science Inc. (the “Company”) was incorporated in the Province of British Columbia on July 18, 2017, under the Business Corporations Act of British Columbia. The Company is in the business of providing topical and transdermal cannabis products under the “Ovation” brand label utilizing patented “Invisicare” delivery technology which it acquired for exclusive use for cannabis formulated products from Skinvisible Pharmaceuticals, Inc. (“Skinvisible”). The Company’s shares are traded on the Canadian Securities Exchange under the symbol “OVAT”.

The Company’s head office is located at Suite 510, 744 West Hastings Street, Vancouver, B.C. V6C 1A5, and its registered office is Suite 704, 595 Howe Street, Vancouver, B.C. V6C 2T5.

These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at September 30, 2019, the Company is not able to finance day to day activities through operations and has incurred losses since inception. The continuing operations of the Company are dependent upon its ability to develop a viable business and to attain profitable operations and generate funds there from. This indicates the existence of a material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern. Management intends to finance operating costs with loans from directors and companies controlled by directors and/or issuance of common shares. If the Company is unable to continue as a going concern, the net realizable value of its assets may be materially less than the amounts on its statement of financial position.

### **2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The accounting policies followed by the Company are set out in Note 2 to the audited annual financial statements for the year ended December 31, 2018 and have been consistently followed in the preparation of these condensed consolidated interim financial statements.

Except as summarized below, the Company used the same accounting policies and methods of computation as in the audited annual financial statements for the year ended December 31, 2018.

#### **Basis of preparation**

##### *Statement of compliance*

These condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) applicable to the preparation of interim financial statements, including International Accounting Standards (“IAS”) 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”).

The condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November 28, 2019.

##### *Basis of measurement*

These condensed consolidated interim financial statements have been prepared on a historical cost basis, modified where applicable. In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting except for cash flow information. The condensed consolidated interim financial statements are presented in Canadian dollars, unless otherwise noted.

##### *Basis of consolidation*

These condensed consolidated interim financial statements include the amounts of the Company and its wholly-owned subsidiary, Ovation Science USA Inc.. All inter-company balances, transactions, income and expenses have been eliminated upon consolidation.

## OVATION SCIENCE INC.

Notes to the Condensed Consolidated Interim Financial Statements  
For the three and nine months ended September 30, 2019 and 2018  
(Expressed in Canadian dollars)  
(Unaudited)

---

---

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Subsidiaries are entities controlled by the Company. Control exists when the Company has power over an entity, when the Company is exposed, or has rights, to variable returns from the entity and when the Company has the ability to affect those returns through its power over the entity. Subsidiaries are included in the condensed consolidated interim financial results of the Company from the effective date of acquisition up to the effective date of disposition or loss of control. Where necessary, adjustments are made to the condensed consolidated interim financial statements of subsidiaries to bring their accounting policies into line with those used by the Company.

#### Cash and cash equivalents

Cash and cash equivalents include cash and highly liquid money market investments that are readily convertible into cash or have terms to maturity at issuance of less than three months.

#### Significant estimates and judgments

The Company makes estimates and assumptions about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions.

In preparing these condensed consolidated interim financial statements, management has made judgments, estimates and assumptions that affect the applicable of the Company's accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates. Management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

In preparing these condensed consolidated interim financial statements, the significant estimates and critical judgments were the same as those applied to the financial statements as at and for the year ended December 31, 2018, except for those summarized below.

#### Effective January 1, 2019, the following standards were adopted

##### *IFRS 16 'Leases' ("IFRS 16")*

Effective January 1, 2019, the Company adopted IFRS 16 which supersedes IAS 17 Leases ("IAS 17"). The Company has applied the new standard using the modified retrospective approach with no restatement of comparative periods. There were no adjustments to retained earnings as a result of adoption. The Company has elected not to reassess whether a contract is, or contains a lease at the date of initial application. Instead, for contracts entered into before the transition date the Company relied on its previous assessment made under IAS 17 and IFRIC 4 Determining whether an arrangement contains a lease. The definition of a lease under IFRS 16 was applied only to contracts entered into or modified on or after January 1, 2019. On adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as operating leases under IAS 17. These liabilities were measured at the present value of the remaining lease payments, discounted using the Company's incremental borrowing rate as of January 1, 2019. Right-of-use assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments.

The Company applied the following practical expedients when adopting IFRS 16 to leases previously classified as operating leases under IAS 17:

- Applied a single discount rate to a portfolio of leases with reasonably similar characteristics;
- Relied on previous assessments on whether leases are onerous;
- Applied the exemption not to recognize right-of-use assets and liabilities for leases where the lease term ends within 12 months of the date of initial application;
- Excluded initial direct costs from the measurement of the right-of-use asset at the date of initial application; and

## OVATION SCIENCE INC.

Notes to the Condensed Consolidated Interim Financial Statements  
For the three and nine months ended September 30, 2019 and 2018  
(Expressed in Canadian dollars)  
(Unaudited)

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

- Used hindsight to determine the lease term where contracts contain options to extend or terminate the lease.

Under IFRS 16, the Company is required to assess the classification of a sublease with reference to the right-of-use asset, not the underlying asset. The Company does not have any subleases. On transition to IFRS 16, the Company did not recognize any lease assets or liabilities as its operating leases had a remaining term of less than 12 months from the date of initial application.

#### Accounting standards issued but not yet effective

The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company has not early adopted any new standards and determined that there are no standards that are relevant to the Company.

### 3. TRADE AND OTHER RECEIVABLES

	September 30, 2019	December 31, 2018
Trade receivables	\$ 24,984	\$ 39,916
GST receivable	20,923	12,280
Accrued interest	15,434	-
	\$ 61,341	\$ 52,196

### 4. INVENTORY

	September 30, 2019	December 31, 2018
Finished goods	\$ 39,682	\$ 25,187
Packaging	28,331	-
Raw materials	28,626	341
	\$ 96,639	\$ 25,528

During the three and nine months ended September 30, 2019, the Company incurred \$4,935 and \$16,689, respectively, (2018 - \$8,518 and \$20,030) in costs of sales related to inventory.

### 5. LICENSE

On September 29, 2017, the Company entered into a License and Assignment Agreement (the "Assignment Agreement") with Skinvisible, whereby Skinvisible granted the Company, the exclusive worldwide right to manufacture, distribute, sell, market, sub-license and promote the Skinvisible product formulations containing derivations of cannabis, including THC, cannabinoids and hemp oil, including the right to use the subject matter of any Skinvisible patents and trademarks which cover the various products or polymer. The agreement shall remain in effect, except for sub-licensees appointed by the Company.

The consideration for the Assignment Agreement is US\$500,000 payable as follows:

- \$312,000 (US\$250,000) within 90 days of execution of this agreement (paid);
- A promissory note for \$294,812 (US\$250,000) due upon the earlier of the Company completing an initial public offering or March 31, 2018, which was later amended to June 30, 2018 and September 15, 2018 (Note 7).

## OVATION SCIENCE INC.

Notes to the Condensed Consolidated Interim Financial Statements  
For the three and nine months ended September 30, 2019 and 2018  
(Expressed in Canadian dollars)  
(Unaudited)

### 5. LICENSE (continued)

On November 10, 2017, the Company entered into a License Agreement (the “Agreement”) with Lighthouse Strategies, LLC (“Lighthouse”), whereby the Company granted to Lighthouse the exclusive right to, utilize the Company’s trademarks, formulations, patents, product specification and the proprietary and patented Invisicare delivery system technology for use with cannabis for US state approved dispensaries only and non exclusive in US states outside dispensaries.

The agreement shall remain in effect with no termination date, unless failure to comply with the terms in the agreement. As part of the consideration related to this agreement, the Company have received a quarterly minimum packaging fee that started at the beginning of June 2018.

Balance, September 30, 2019 and December 31, 2018	\$	606,812
---	----	---------

### 6. ACCOUNTS PAYABLE AND OTHER LIABILITIES

	September 30, 2019	December 31, 2018
Accounts payable	\$ 11,530	\$ 15,010
Accrued liabilities	49,324	37,474
Due to related parties	37,825	-
	\$ 98,679	\$ 52,484

### 7. CONVERTIBLE NOTES

(i) On June 28, 2018 and June 29, 2018, the Company issued unsecured convertible notes for proceeds of \$50,000 and \$100,000, respectively. The convertible notes are unsecured, bear interest at 10% per annum and are due on August 28, 2019 and August 29, 2019, respectively. The \$100,000 convertible note was issued to a director of the Company. At any time after issuance, the holder is entitled to convert, at their sole discretion, all or a portion of the principal amount into common shares of the Company at a value of \$0.30 principal per share. These convertible notes include both a liability component for the contractual cash flows and an equity component for the conversion feature. The liability component was valued first based on the present value of contractual cash flows using a discount rate of 12% which is the estimated rate that would have been charged for a similar instrument without a conversion feature. The equity component of \$3,245 was measured based on the residual value of the compound instrument as a whole after deducting the amount determined separately for the liability component.

(ii) On August 14, 2018, the Company issued a convertible promissory note to an arm’s length party for a principal amount of CAD\$130,870 (US\$100,000). The note is unsecured, bears interest at 10% per annum, and is due October 14, 2019.

At any time after issuance, the holder is entitled to convert, at their sole discretion, all or a portion of the principal amount into common shares of the Company at a value of CAD \$0.30 principal per share.

As the note is issued in a currency different from the Company’s functional currency, the conversion feature is treated as a derivative liability and recorded at fair value. The value of the derivative liability was calculated first, with the remaining face value of the loan attributed to the debt host component.

The following table summarizes the continuity of the liability components of the Company’s convertible notes issued on June 28, 2018, June 29, 2018 and August 14, 2018:

	Note (i)	Note (ii)	Total
As at December 31, 2018	\$ 148,480	131,250	279,730
Accretion	1,520	5,028	6,548
As at September 30, 2019	\$ 150,000	136,278	286,278

**OVATION SCIENCE INC.**

Notes to the Condensed Consolidated Interim Financial Statements  
For the three and nine months ended September 30, 2019 and 2018  
(Expressed in Canadian dollars)  
(Unaudited)

**7. CONVERTIBLE NOTES (continued)**

During the three and nine months ended September 30, 2019, interest expense of \$2,452 and \$9,890, respectively, (2018 - \$3,781 and \$3,836) and accretion expense of \$378 and \$1,519, respectively, (2018 - \$583 and \$1,149) was recorded for the convertible notes issued on June 28, 2018 and June 29, 2018. As at September 30, 2019, these convertible notes remain outstanding.

During the three and nine months ended September 30, 2019, interest expense of \$3,327 and \$9,939, respectively, (2018 - \$1,667 and \$1,667) and accretion expense of \$1,712 and \$5,048, respectively, (2018 - \$3,109 and \$3,109) was recorded for the convertible note issued on August 14, 2018. As at September 30, 2019, these convertible notes remain outstanding.

*Derivative Liability*

The conversion option on the convertible note denominated in U.S. dollars has been accounted for as a derivative liability as the number of shares or units issuable on conversion will vary as a result of changes in foreign exchange rates. A continuity of the derivative liability is as follows:

As at December 31, 2018	\$	58,845
Net change in fair value of liability		(47,224)
As at September 30, 2019	\$	11,621

The fair value of the derivative liability was estimated using the Black-Scholes Option Pricing model using the following assumptions:

	<b>September 30, 2019</b>
Expected life	0.04
Volatility	124%
Risk free interest rate	1.59%
Dividend yield rate	0.00%

**8. SHARE CAPITAL**

During the nine months ended September 30, 2019, the company issued 60,000 common shares for the exercise of 60,000 stock options at \$0.30 for cash proceeds of \$18,000.

During the nine months ended September 30, 2019, the company issued 21,510 common shares for the exercise of 21,510 broker warrants at \$0.45 for cash proceeds of \$9,680.

**OVATION SCIENCE INC.**

Notes to the Condensed Consolidated Interim Financial Statements  
 For the three and nine months ended September 30, 2019 and 2018  
 (Expressed in Canadian dollars)  
 (Unaudited)

**9. RESERVES****Stock option plan**

The Directors of the Company adopted a stock option plan on April 10, 2018 (the “Plan”). The Plan provides that, subject to the requirements of the Canadian Securities Exchange, the aggregate number of securities reserved for issuance will be 10% of the number of the Company’s Common Shares issued and outstanding at the time such options are granted. The Plan provides that the number of Common Shares that may be reserved for issuance to any one individual upon exercise of all stock options held by such individual may not exceed 5% of the issued Common Shares, if the individual is a director, officer, employee or consultant, or 1% of the issued Common Shares, if the individual is engaged in providing investor relations services, on a yearly basis. All options granted under the Plan will expire not later than the date that is ten years from the date that such options are granted. Options terminate earlier as follows: (i) immediately in the event of dismissal with cause; (ii) 90 days from date of termination other than for cause; or (iii) one year from the date of death or disability.

**Stock options**

On January 8, 2019, the Company granted 100,000 stock options to a consultant of the Company. The options entitle the holders to acquire common shares of the Company at \$0.30 per share and expire on January 8, 2021. During the nine months ended September 30, 2019, the Company recorded share-based payment expense of \$14,432, for these options. The stock options were valued using the Black Scholes Option Pricing model using the following assumptions: share price: \$0.30, expected life: one year, expected volatility: 127%, dividend yield: 0%, and risk-free interest rate: 1.88%.

A summary of stock option activity for the nine months ending September 30, 2019 is as follows:

	<b>Options</b>	<b>Weighted average exercise price</b>
Outstanding, January 1, 2019	1,150,000	\$ 0.30
Granted	100,000	0.30
Exercised	(60,000)	0.30
Expired	(40,000)	-
Outstanding, September 30, 2019	1,150,000	0.30
Exercisable, September 30, 2019	1,150,000	\$ 0.30

As at September 30, 2019, the following stock options were outstanding:

<b>Numbers of options</b>	<b>Exercise price</b>	<b>Expiry date</b>
1,150,000	\$ 0.30	April 10, 2020
1,150,000		

At September 30, 2019, the weighted-average remaining contractual life of options outstanding is 0.53 years.

**Warrants**

A summary of warrant activity for the nine months ending September 30, 2019 is as follows:

	<b>Warrants</b>	<b>Weighted average exercise price</b>
Outstanding, January 1, 2019	4,669,000	\$ 0.45
Exercised	(21,510)	0.45
Outstanding, September 30, 2019	4,647,490	0.45
Exercisable, September 30, 2019	4,647,490	\$ 0.45

## OVATION SCIENCE INC.

Notes to the Condensed Consolidated Interim Financial Statements  
For the three and nine months ended September 30, 2019 and 2018  
(Expressed in Canadian dollars)  
(Unaudited)

### 9. RESERVES (continued)

As at September 30, 2019, the following warrants were outstanding:

Numbers of warrants	Exercise price	Expiry date
4,647,490	\$ 0.45	November 15, 2020
4,647,490		

As at September 30, 2019, the weighted-average remaining contractual life of warrants outstanding is 1.13 years

### 10. RELATED PARTY TRANSACTIONS

#### *Key management compensation*

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company's Board of Directors and corporate officers. The remuneration of directors and key management personnel is as follows:

	September 30, 2019	September 30, 2018
Management fees	\$ 261,058	\$ 148,500
Director fees	1,800	-
Share-based payments	-	12,980
	\$ 262,858	\$ 161,480

#### *Related party balances*

On September 12, 2019, Ovation Science USA Inc. purchased furniture and lab equipment from a company with two common directors for \$98,963 (\$75,000 USD).

As at September 30, 2019, due to related parties of \$37,825 (December 31, 2018 - \$144,782) consists of accrued interest and management fees due to related parties, which are included in the accounts payable account. These amounts are non-interest bearing, unsecured and due on demand.

### 11. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to safeguard its ability to continue as a going concern in order to pursue its operations and to maintain a flexible capital structure, which optimizes the costs of capital at an acceptable risk. The Company considers its capital for this purpose to be its promissory notes, convertible notes and shareholders' equity.

The Company's primary source of capital is through the issuance of convertible notes and equity. The Company manages and adjusts its capital structure when changes in economic conditions occur. To maintain or adjust the capital structure, the Company may seek additional funding. The Company may require additional capital resources to meet its administrative overhead expenses in the long term. The Company believes it will be able to raise capital as required in the long term but recognizes there will be risks involved that may be beyond its control. There are no external restrictions on the management of capital.

**OVATION SCIENCE INC.**

Notes to the Condensed Consolidated Interim Financial Statements  
For the three and nine months ended September 30, 2019 and 2018  
(Expressed in Canadian dollars)  
(Unaudited)

---

---

**12. SUBSEQUENT EVENTS**

On October 8, 2019, the Company granted stock options to two directors and a consultant to purchase a total of 300,000 common shares of the Company. Each option granted can be exercised to purchase one common share of the Company at \$0.30 per share and expires two years from the date of issuance. The options vest immediately.